Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions.
Newco Elkedonia SAS has raised €11 million (US$12.7 million) in a seed round, which will fund it to take a potentially first-in-class ELK-1 inhibitor into the clinic in the treatment of refractory depression. ELK-1 plays a pivotal role in neuroplasticity and in reward circuits in the brain, which when disrupted can lead to depression, addiction and post-traumatic stress disorder.
Betta Pharmaceuticals Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising a VHL-binding agent coupled to a GTPase KRAS-targeting moiety through a linker acting as KRAS degradation inducers reported to be useful for the treatment of cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has divulged compounds acting as apolipoprotein A (ApoA; LPA) inhibitors reported to be useful for the treatment of hyperlipidemia, coronary heart disease, ischemic stroke and myocardial infarction.
Shanghai Tyk Medicines Co. Ltd. and Tyk Medicines Inc. have identified poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Researchers at Gachon University and Seoul National University Hospital have synthesized a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4; aggrecanase-1) inhibitors reported to be useful for the treatment of hepatic fibrosis.
Haisco Pharmaceutical Group Co. Ltd. has disclosed compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes and obesity.
Doxorubucin is an effective therapeutic in cancer treatment, but it can cause cardiotoxicity and damage the mitochondrial machinery. A new patient-derived and mitochondria-rich human induced pluripotent stem cell derived-cardiomyocyte (hiPSC-CM) model protected by dexrazoxane was developed.
Vascular endothelial factor receptor 2 (VEGFR-2) is an attractive target for cancer drugs because inhibiting it prevents tumors from developing the blood vessels that they require for rapid growth. Several VEGFR-2 inhibitors have already been licensed for the clinic.
RSS
